RUTHERFORD, N.J., Feb. 26, 2025 (GLOBE NEWSWIRE) — Glucotrack, Inc. (Nasdaq: GCTK), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced today that Guillermo Umpierrez, MD, CDCES, FACE, MACP, has been named as Glucotrack’s new Medical Advisory Board member, effective immediately.
“With his invaluable experience in diabetes care and his dedication to improving the lives of people with diabetes, Dr. Umpierrez brings exceptional clinical and research expertise that will be instrumental as we advance our novel Continuous Blood Glucose Monitoring (CBGM) technology through clinical development,” said Paul V. Goode, PhD, President and Chief Executive Officer of Glucotrack. “His deep understanding of glucose monitoring will be particularly valuable as we progress into human clinical trials. We look forward to having his thought leadership guide us as we continue towards our goal of making glucose monitoring less burdensome for those living with diabetes.”
Dr. Guillermo Umpierrez is a Professor of Medicine at Emory University School of Medicine and past president of the American Diabetes Association for Medicine and Science. Through his extensive experience leading and participating in clinical research, Dr. Umpierrez has significantly advanced the understanding and treatment of diabetes, particularly in hospitalized patients. As Editor-in-Chief of the American Diabetes Association Therapy for Diabetes Mellitus and Related Disorders textbook, he has published over 500 scientific manuscripts and book chapters. Dr. Umpierrez has received numerous teaching awards and national recognitions from organizations including the American College of Physicians, American Association of Clinical Endocrinologists, Endocrine Society, Diabetes Technology Society, and American Diabetes Association. He is board-certified in Internal Medicine and Endocrinology, a Fellow of the American Association of Clinical Endocrinology and a Master of the American College of Physicians. As director of the Emory Latino Diabetes Education Program, a nationally accredited Spanish Diabetes education program, he continues to advance diabetes care and education in the Latino community.
Glucotrack’s Medical Advisory Board provides strategic guidance to Glucotrack as the Company advances development of its innovative CBGM system, which is designed to directly measure blood glucose levels without the measurement lag time associated with traditional continuous glucose monitoring systems that measure glucose in interstitial fluid. With a sensor life of 3 years and no wearable component, the CBGM system aims to address the limitations of existing glucose monitoring solutions including real-time accuracy, longevity, comfort, wearability and supply management. The CBGM is designed for a less intrusive approach to continuous glucose monitoring.
Dr. Umpierrez said: “I am honored to be joining Glucotrack’s Medical Advisory Board. The Company’s innovative approach to continuous blood glucose monitoring through its implantable CBGM technology represents a potentially significant advancement in diabetes care. Having followed the encouraging results from their first-in-human studies, I look forward to contributing to the clinical development of this promising technology as a new approach for many people living with diabetes.”
For more information about Glucotrack’s CBGM technology, visit glucotrack.com. Information on the Company’s website does not constitute a part of and is not incorporated by reference into this press release.
About Glucotrack, Inc.
Glucotrack, Inc. (NASDAQ: GCTK) is focused on the design, development, and commercialization of novel technologies for people with diabetes. The Company is currently developing a long-term implantable continuous blood glucose monitoring system for people living with diabetes.
Glucotrack’s CBGM is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 3 years, no on-body wearable component and with minimal calibration. For more information, please visit http://www.glucotrack.com.
